Australian (ASX) Stock Market Forum

GLP-1 agonists; diabetes drug and now weight loss

Jump to new
Seen a few critical takes on artificially mega boosting a GLP-1 agonist that would make me very wary.
Following this doc's commentary - the GLP-1 receptors are found all through the body and in major organs such as brain, kidney, lung etc and also have a role in the immune system. But they don't know what their function is in each location. People taking the agonist are unwitting sources of 'market data' as there are no long term studies of high dose semaglutide treatment, i.e it's a fkg experiment. Users could be inflicting malnutrition on themselves due to blunted appetite and causing muscle and connective tissue loss. Increase in the number of fat cells even though smaller in size? Elsewhere I heard it might cause the body to lose its ability to manufacture its own intrinsic GLP-1 agonists .. anyway you can check it out for yourself?

 
from the story:
Her death certificate states the cause was an acute gastrointestinal illness. While the coroner’s conclusion does not draw any direct link to the weight loss medication, Roy believes that the drugs contributed to her death
Click to expand...
they'll be looking closer, as time passes, I'd suspect.

There was also a 60 Minutes program on the topic, over the weekend.
 
That resonates a bit with the stomach/digestive paralysis that the doc said can occur to a few. Digestion gets slowed down inducing early satiety but in a few can lead to 'gastroparesis' and marooned food starts rotting in the alimentary tract which would also explain the brownness and trying to vomit it up.
Someone else (a gastric band surgeon) said GLP-1 is a neurotransmitter that by being injected as a megadose and reaching the bloodstream becomes effectively a hormone.

A condition that affects the stomach muscles and prevents proper stomach emptying.
Gastroparesis can affect digestion. The cause might be damage to a nerve that controls stomach muscles
Click to expand...
 
This surgeon guy is very thorough and analytical and takes a while to achieve lift-off but comes across as very credible to me despite his speciality - weight loss via gastric band surgery. He addresses skepticism about his impartiality at the end.

 
Dona Ferentes said:
And a researchers' paradise, going forward
Click to expand...
New data indicates that patients who underwent treatment with Eli Lilly's groundbreaking weight loss drug, Zepbound, faced weight regain after discontinuing the medication for a year. This revelation emerges from a comprehensive study funded by Eli Lilly, spanning 88 weeks, underscoring the critical role of sustained therapy in maintaining substantial weight loss.

The complete study findings, which were published in the esteemed research journal JAMA, have had far-reaching implications, leading to a more than 3% drop in Eli Lilly's stock on Monday following their release. These results shed light on the challenging and dynamic landscape of weight management, with potentially game-changing implications for pharmaceutical interventions.

Zepbound, alongside Novo Nordisk's weight loss injection Wegovy and their popular diabetes medications, has experienced soaring popularity due to their remarkable ability to help patients achieve significant weight loss without resorting to surgery. In light of these findings, some Wall Street analysts have even speculated that Zepbound, sharing an active ingredient with Eli Lilly's diabetes drug Mounjaro, might have the potential to become one of the best-selling drugs of all time.

The study on Eli Lilly's treatment involved 670 obese patients without diabetes, who, over 36 weeks, witnessed an average weight loss of approximately 20% of their body weight through Zepbound. Subsequently, half of these patients continued with the drug for an additional 52 weeks, while the remaining half transitioned to a placebo for the subsequent year.

For those who persisted with Zepbound, they enjoyed an additional 6.7% decrease in weight on average between weeks 36 to 88. In contrast, those who ceased the medication experienced a regain of 14.8% of their weight. Importantly, those who discontinued Zepbound still concluded the 88-week study with 9.9% less weight than their starting point, signifying that they had regained approximately half of their initial weight loss.

Dr. Louis Aronne, the study's lead author and a prominent expert in obesity medicine and metabolic research at Weill Cornell Medicine in New York City, emphasized the importance of these findings, stating, "If you look at the magnitude of the weight gain, they gain back about half the weight they had originally lost over a one-year period of time."

The study also highlighted that approximately 17% of individuals who ceased Zepbound managed to maintain at least 80% of their initial weight loss, while an impressive 90% of those who continued with the treatment succeeded in maintaining at least 80% of their weight loss.
 
from the wires:

What’s next for Ozempic?​

Scientists are exploring whether the new diabetes and weight-loss drugs could also treat addiction, kidney disease and more.

Dani Blum - New York Times

Ozempic and other drugs like it have proved powerful at regulating blood sugar and driving weight loss. Now, scientists are exploring whether they might be just as transformative in treating a wide range of other conditions, from addiction and liver disease to a common cause of infertility.

If these new drugs that have been found to help weight loss can treat even more diseases, they could shake up medicine all over again.

Much of the research on other uses of semaglutide, the compound in Ozempic and Wegovy, and tirzepatide, the substance in Mounjaro and Zepbound, is only in the early stages. Some of the biggest questions scientists are seeking to answer: Do the benefits of these drugs just boil down to weight loss? Or do they have other effects, like tamping down inflammation in the body or quieting the brain’s compulsive thoughts, that would make it possible to treat far more illnesses?

We probably won’t know anytime soon. “We’re still learning how these medicines work,” says Dr Daniel Drucker, one of the first researchers to study these drugs. (Drucker consults for Novo Nordisk, the company that makes Ozempic and Wegovy.)

People with the conditions outlined below, many of whom have few good options for treatment, could benefit in the long run if these trials are successful. And for weight-loss drugmakers, every new use could catapult the drugs even further into blockbuster status.
With some of these applications – including for heart disease and sleep apnoea - .....as evidence emerges from these studies, researchers will get a clearer idea of how, exactly, these drugs work in the body. If they can treat even more diseases, they could shake up medicine all over again.

Alcohol use disorder​

The issue: Alcohol use disorder, also known as alcoholism, is common – nearly 30 million people in the United States had the condition in 2022. But it’s rare for people to get diagnosed, and often extraordinarily difficult for them to find treatment. There are effective medications on the market, but some people who could benefit from them aren’t even aware that they exist.
The potential: Anecdotally, some people who take drugs like Ozempic say the medications make them want to drink less, and in some cases, turn them off alcohol altogether. Researchers are trying to untangle why.
Because people feel full when they take these medications, they may lose interest in alcohol as well as in food. It’s also possible that because these drugs target parts of the brain that regulate appetite, they could also affect compulsive behaviours that might involve those brain regions, like using alcohol or stimulants, gambling, smoking or even nail-biting.
The early evidence: One small study followed six people with alcohol use disorder who were taking semaglutide for weight loss. All six drank significantly less after they had been on the drug for one to nine months. In an online survey of 153 adults with obesity, most of whom were white and women, those who took semaglutide or tirzepatide reported drinking significantly less than peers not on the medications.
While data is limited, some patients with alcohol use disorder have already started asking doctors about these drugs. Researchers studying how these medications affect drinking recently responded to that demand with a piece in Nature Medicine, urging doctors not to use the drugs for alcohol use disorder without more research.

Polycystic ovary syndrome​

The issue: As many as 5 million people in the United States have polycystic ovary syndrome, or PCOS. The condition is a leading cause of infertility and causes irregular periods. There are treatments available – diet and exercise changes, birth control pills and the diabetes drug metformin – but they don’t work for everyone.
The potential: Researchers believe high testosterone levels contribute to PCOS. When people with the condition lose weight, their testosterone levels often decline. Drugs like Ozempic could help regulate hormones in people with PCOS, says Dr Melanie Cree, who is leading one of the earliest studies to investigate whether semaglutide can resolve PCOS symptoms.
The early evidence: A small study of 27 people with obesity and PCOS who took a low dose of semaglutide found that after six months, most participants had lost weight and had more regular periods, suggesting their PCOS was under better control. Cree completed a study of semaglutide in adolescent girls with PCOS that showed similar results, and she is recruiting for another focused on period regularity.

Liver disease​

The issue: Up to 70 per cent of people with type 2 diabetes and 50 per cent to 90 per cent of people with obesity have nonalcoholic fatty liver disease, or NAFLD, which occurs when excess fat builds up in the liver. The condition can cause liver damage so severe that some patients end up needing liver transplants.
The potential: Doctors typically urge obese or overweight patients with NAFLD to lose weight to lower the amount of fat and inflammation in the liver. Because drugs like Ozempic lead people to lose weight, they may also decrease the amount of fat stored in the liver. Type 2 diabetes also increases the risk of NAFLD. By treating it, drugs like Ozempic may also reduce the risk or severity of liver disease.
Scientists have two other theories about how the drugs might help: by improving the insulin resistance common in people with NAFLD and lowering inflammation that can damage the liver.
The early evidence: A Novo Nordisk-funded study found that compared with placebo, semaglutide didn’t significantly improve liver scarring or resolution of nonalcoholic steatohepatitis, or NASH, a severe form of nonalcoholic fatty liver disease. The study included people with cirrhosis, or scarred and permanently damaged livers.
A larger Novo Nordisk-funded trial found that patients in earlier stages taking semaglutide were more likely than those on a placebo to see their NASH resolved, but not significantly more likely to see their scarring improve.
Novo Nordisk is now running an even bigger clinical trial on semaglutide and NASH, and the Food and Drug Administration has designated the drug a “breakthrough therapy” for the disease, which will expedite regulatory review. Researchers funded by Eli Lilly are also investigating whether tirzepatide can treat NASH.

Cardiovascular issues​

The issue: Heart disease killed nearly 700,000 people in the United States in 2022, making it the country’s leading cause of death. Experts say there’s an urgent need for new therapies that can reduce the risk of heart attacks and strokes and improve symptoms such as fatigue and shortness of breath that can make it difficult for people with heart disease to get through the day.
The potential: Obesity significantly raises the risk of cardiovascular disease, which is why some doctors think that losing weight might treat and prevent heart issues. The drugs may also be able to help by lowering inflammation, which may lead plaque to form in the heart and trigger blood clots.
The early evidence: In November, a major trial showed that semaglutide lowered the risk of events like heart attacks and strokes by 20 per cent among obese and overweight people with heart disease. Another trial of people with obesity and a certain type of heart failure found that semaglutide could improve symptoms and make it easier to exercise.
Eli Lilly is conducting its own trial on tirzepatide and heart failure. And more studies are in the pipeline: Researchers are examining whether semaglutide can reduce plaque in the heart, improve symptoms of heart failure or reduce damage from strokes.

Sleep apnoea​

The issue: An estimated 30 million people in the United States suffer from obstructive sleep apnoea, in which breathing repeatedly stops and starts during sleep. Treatments like the use of continuous positive airway pressure, or CPAP, machines can help, although patients often find them uncomfortable. Many with sleep apnoea are undiagnosed. If it isn’t properly treated, the condition can take a significant toll on people’s health and can raise the risk of complications like heart disease and type 2 diabetes.
The potential: Sleep apnoea is more common among people with obesity. That’s due to a complex set of factors, including that deposits of fat in the neck can clog the airway when a person is lying down. Research has shown weight loss, including through bariatric surgery, can help.
The early evidence: There’s very little data so far, although a spokesperson for Eli Lilly said the company expected to complete a study of tirzepatide and sleep apnoea in spring 2024. Novo Nordisk is not currently studying whether semaglutide can treat sleep apnoea.

Kidney disease​

The issue: Roughly 1 in 3 adults with type 2 diabetes also has chronic kidney disease, which occurs when the kidneys are damaged and can’t function properly. Patients with the disease may ultimately need dialysis or a kidney transplant, and if it goes untreated, the condition can be fatal.
The potential: Kidney damage happens slowly over time and is irreversible in almost all cases, said Dr George Bakris, who was involved in a trial of semaglutide in people with type 2 diabetes and chronic kidney disease that was backed by Novo Nordisk. Drugs like Ozempic may be able to prevent further damage, partly because weight loss reduces the risk of high blood pressure and type 2 diabetes, which are risk factors for chronic kidney disease.
It is not totally clear how else these drugs might improve chronic kidney disease, but one potential factor is that they might reduce inflammation, which can be harmfully high in people with the condition.
The early evidence: Novo Nordisk announced in October that it had halted a trial of semaglutide in people with type 2 diabetes and chronic kidney disease after an early analysis made clear the drug was effective, although the company has not yet released the data. The company is funding another study to examine how semaglutide works in the kidneys. Eli Lilly is funding a trial of tirzepatide in people with obesity and chronic kidney disease.
These and other studies are part of what Dr Howard Forman, a professor at the Yale School of Medicine who specialises in health policy, calls “an explosion of opportunities”.
Whether those opportunities can become new treatments remains to be seen.“We are on the very, very early upsweep of this whole industry,” Forman says, “and nothing will surprise me".
 
Dona Ferentes said:
from the wires:

What’s next for Ozempic?​

Scientists are exploring whether the new diabetes and weight-loss drugs could also treat addiction, kidney disease and more.

Dani Blum - New York Times

Ozempic and other drugs like it have proved powerful at regulating blood sugar and driving weight loss. Now, scientists are exploring whether they might be just as transformative in treating a wide range of other conditions, from addiction and liver disease to a common cause of infertility.

If these new drugs that have been found to help weight loss can treat even more diseases, they could shake up medicine all over again.

Much of the research on other uses of semaglutide, the compound in Ozempic and Wegovy, and tirzepatide, the substance in Mounjaro and Zepbound, is only in the early stages. Some of the biggest questions scientists are seeking to answer: Do the benefits of these drugs just boil down to weight loss? Or do they have other effects, like tamping down inflammation in the body or quieting the brain’s compulsive thoughts, that would make it possible to treat far more illnesses?

We probably won’t know anytime soon. “We’re still learning how these medicines work,” says Dr Daniel Drucker, one of the first researchers to study these drugs. (Drucker consults for Novo Nordisk, the company that makes Ozempic and Wegovy.)

People with the conditions outlined below, many of whom have few good options for treatment, could benefit in the long run if these trials are successful. And for weight-loss drugmakers, every new use could catapult the drugs even further into blockbuster status.
With some of these applications – including for heart disease and sleep apnoea - .....as evidence emerges from these studies, researchers will get a clearer idea of how, exactly, these drugs work in the body. If they can treat even more diseases, they could shake up medicine all over again.

Alcohol use disorder​

The issue: Alcohol use disorder, also known as alcoholism, is common – nearly 30 million people in the United States had the condition in 2022. But it’s rare for people to get diagnosed, and often extraordinarily difficult for them to find treatment. There are effective medications on the market, but some people who could benefit from them aren’t even aware that they exist.
The potential: Anecdotally, some people who take drugs like Ozempic say the medications make them want to drink less, and in some cases, turn them off alcohol altogether. Researchers are trying to untangle why.
Because people feel full when they take these medications, they may lose interest in alcohol as well as in food. It’s also possible that because these drugs target parts of the brain that regulate appetite, they could also affect compulsive behaviours that might involve those brain regions, like using alcohol or stimulants, gambling, smoking or even nail-biting.
The early evidence: One small study followed six people with alcohol use disorder who were taking semaglutide for weight loss. All six drank significantly less after they had been on the drug for one to nine months. In an online survey of 153 adults with obesity, most of whom were white and women, those who took semaglutide or tirzepatide reported drinking significantly less than peers not on the medications.
While data is limited, some patients with alcohol use disorder have already started asking doctors about these drugs. Researchers studying how these medications affect drinking recently responded to that demand with a piece in Nature Medicine, urging doctors not to use the drugs for alcohol use disorder without more research.

Polycystic ovary syndrome​

The issue: As many as 5 million people in the United States have polycystic ovary syndrome, or PCOS. The condition is a leading cause of infertility and causes irregular periods. There are treatments available – diet and exercise changes, birth control pills and the diabetes drug metformin – but they don’t work for everyone.
The potential: Researchers believe high testosterone levels contribute to PCOS. When people with the condition lose weight, their testosterone levels often decline. Drugs like Ozempic could help regulate hormones in people with PCOS, says Dr Melanie Cree, who is leading one of the earliest studies to investigate whether semaglutide can resolve PCOS symptoms.
The early evidence: A small study of 27 people with obesity and PCOS who took a low dose of semaglutide found that after six months, most participants had lost weight and had more regular periods, suggesting their PCOS was under better control. Cree completed a study of semaglutide in adolescent girls with PCOS that showed similar results, and she is recruiting for another focused on period regularity.

Liver disease​

The issue: Up to 70 per cent of people with type 2 diabetes and 50 per cent to 90 per cent of people with obesity have nonalcoholic fatty liver disease, or NAFLD, which occurs when excess fat builds up in the liver. The condition can cause liver damage so severe that some patients end up needing liver transplants.
The potential: Doctors typically urge obese or overweight patients with NAFLD to lose weight to lower the amount of fat and inflammation in the liver. Because drugs like Ozempic lead people to lose weight, they may also decrease the amount of fat stored in the liver. Type 2 diabetes also increases the risk of NAFLD. By treating it, drugs like Ozempic may also reduce the risk or severity of liver disease.
Scientists have two other theories about how the drugs might help: by improving the insulin resistance common in people with NAFLD and lowering inflammation that can damage the liver.
The early evidence: A Novo Nordisk-funded study found that compared with placebo, semaglutide didn’t significantly improve liver scarring or resolution of nonalcoholic steatohepatitis, or NASH, a severe form of nonalcoholic fatty liver disease. The study included people with cirrhosis, or scarred and permanently damaged livers.
A larger Novo Nordisk-funded trial found that patients in earlier stages taking semaglutide were more likely than those on a placebo to see their NASH resolved, but not significantly more likely to see their scarring improve.
Novo Nordisk is now running an even bigger clinical trial on semaglutide and NASH, and the Food and Drug Administration has designated the drug a “breakthrough therapy” for the disease, which will expedite regulatory review. Researchers funded by Eli Lilly are also investigating whether tirzepatide can treat NASH.

Cardiovascular issues​

The issue: Heart disease killed nearly 700,000 people in the United States in 2022, making it the country’s leading cause of death. Experts say there’s an urgent need for new therapies that can reduce the risk of heart attacks and strokes and improve symptoms such as fatigue and shortness of breath that can make it difficult for people with heart disease to get through the day.
The potential: Obesity significantly raises the risk of cardiovascular disease, which is why some doctors think that losing weight might treat and prevent heart issues. The drugs may also be able to help by lowering inflammation, which may lead plaque to form in the heart and trigger blood clots.
The early evidence: In November, a major trial showed that semaglutide lowered the risk of events like heart attacks and strokes by 20 per cent among obese and overweight people with heart disease. Another trial of people with obesity and a certain type of heart failure found that semaglutide could improve symptoms and make it easier to exercise.
Eli Lilly is conducting its own trial on tirzepatide and heart failure. And more studies are in the pipeline: Researchers are examining whether semaglutide can reduce plaque in the heart, improve symptoms of heart failure or reduce damage from strokes.

Sleep apnoea​

The issue: An estimated 30 million people in the United States suffer from obstructive sleep apnoea, in which breathing repeatedly stops and starts during sleep. Treatments like the use of continuous positive airway pressure, or CPAP, machines can help, although patients often find them uncomfortable. Many with sleep apnoea are undiagnosed. If it isn’t properly treated, the condition can take a significant toll on people’s health and can raise the risk of complications like heart disease and type 2 diabetes.
The potential: Sleep apnoea is more common among people with obesity. That’s due to a complex set of factors, including that deposits of fat in the neck can clog the airway when a person is lying down. Research has shown weight loss, including through bariatric surgery, can help.
The early evidence: There’s very little data so far, although a spokesperson for Eli Lilly said the company expected to complete a study of tirzepatide and sleep apnoea in spring 2024. Novo Nordisk is not currently studying whether semaglutide can treat sleep apnoea.

Kidney disease​

The issue: Roughly 1 in 3 adults with type 2 diabetes also has chronic kidney disease, which occurs when the kidneys are damaged and can’t function properly. Patients with the disease may ultimately need dialysis or a kidney transplant, and if it goes untreated, the condition can be fatal.
The potential: Kidney damage happens slowly over time and is irreversible in almost all cases, said Dr George Bakris, who was involved in a trial of semaglutide in people with type 2 diabetes and chronic kidney disease that was backed by Novo Nordisk. Drugs like Ozempic may be able to prevent further damage, partly because weight loss reduces the risk of high blood pressure and type 2 diabetes, which are risk factors for chronic kidney disease.
It is not totally clear how else these drugs might improve chronic kidney disease, but one potential factor is that they might reduce inflammation, which can be harmfully high in people with the condition.
The early evidence: Novo Nordisk announced in October that it had halted a trial of semaglutide in people with type 2 diabetes and chronic kidney disease after an early analysis made clear the drug was effective, although the company has not yet released the data. The company is funding another study to examine how semaglutide works in the kidneys. Eli Lilly is funding a trial of tirzepatide in people with obesity and chronic kidney disease.
These and other studies are part of what Dr Howard Forman, a professor at the Yale School of Medicine who specialises in health policy, calls “an explosion of opportunities”.
Whether those opportunities can become new treatments remains to be seen.“We are on the very, very early upsweep of this whole industry,” Forman says, “and nothing will surprise me".
Click to expand...
Or in a non medical view, if you are obese or overweight, you snore, are unfit, have cardio, liver and reproductive system issues, etc...
Do I get a Nobel prize?
Or does it conflict with the new dogma fat is beautiful with overweight models and I am beautiful inside BS on media..
 
hmmm !

so i prefer FPH over RMD ( as i crunch the numbers )

but currently hold neither share

should i be calculating an acceptable entry price , i wonder

the old 'wonder drug story ' maybe it is true this time

i love the trend for shortened tests ( as soon as they get a news-worthy result ) makes you wonder whether they are looking for headlines or cures , doesn't it ?
 
from the wires..
.
"This drug story started in the 1970s with the discovery that the hormone GLP-1 (glucagon-like-peptide-1) regulated blood sugar better than insulin for diabetics. But when GLP-1 was injected, it degraded before reaching the pancreas. GLP-1 was a failure.

"Then in the early 2000s, they extracted the saliva from a North American Gila monster (a venomous lizard) and injected it into rats. This sounds like a horror movie, but it’s 21st-century pharmaceutical R&D. The saliva was used to synthesise the first GLP-1 drugs that the body did not reject. GLP-1 became a phenomenal success.

The second wave of the GLP-1 drugs (liraglutide) by Novo Nordisk in 2010 had a peculiar side effect – injected rats starved themselves to death. Which is horrific, but it’s also interesting. With lower doses, rats ate less. When launched as the weight loss drug Saxenda in 2014, people lost 5 per cent of their body weight in a year.

The third wave of the GLP-1 diabetes drugs (semaglutide) was launched in 2017 by Novo Nordisk under the brand name Ozempic. Then things really took off. Ozempic was approved only for diabetes, but patients lost 15 per cent of their body weight in a year.
The drug was rebranded for weight loss in 2021 as Wegovy. Interestingly, it seemed to also curb compulsive behaviours such as drinking alcohol, gambling and smoking.

The point of this history lesson is there is half a century of dedicated research behind these drugs. Yet, the drugs are not without their challenges. The long-term side effects are unknown – only time will reveal this.

Ozempic is expensive at $US1300 per month. If you stop taking it, you pile the weight back on. The drugs work so there’s high willingness to pay, which makes it a great business model. How society pays for them without bankrupting our healthcare system will be a big problem....
 
Dona Ferentes said:
from the wires..
.
"This drug story started in the 1970s with the discovery that the hormone GLP-1 (glucagon-like-peptide-1) regulated blood sugar better than insulin for diabetics. But when GLP-1 was injected, it degraded before reaching the pancreas. GLP-1 was a failure.

"Then in the early 2000s, they extracted the saliva from a North American Gila monster (a venomous lizard) and injected it into rats. This sounds like a horror movie, but it’s 21st-century pharmaceutical R&D. The saliva was used to synthesise the first GLP-1 drugs that the body did not reject. GLP-1 became a phenomenal success.

The second wave of the GLP-1 drugs (liraglutide) by Novo Nordisk in 2010 had a peculiar side effect – injected rats starved themselves to death. Which is horrific, but it’s also interesting. With lower doses, rats ate less. When launched as the weight loss drug Saxenda in 2014, people lost 5 per cent of their body weight in a year.

The third wave of the GLP-1 diabetes drugs (semaglutide) was launched in 2017 by Novo Nordisk under the brand name Ozempic. Then things really took off. Ozempic was approved only for diabetes, but patients lost 15 per cent of their body weight in a year.
The drug was rebranded for weight loss in 2021 as Wegovy. Interestingly, it seemed to also curb compulsive behaviours such as drinking alcohol, gambling and smoking.

The point of this history lesson is there is half a century of dedicated research behind these drugs. Yet, the drugs are not without their challenges. The long-term side effects are unknown – only time will reveal this.

Ozempic is expensive at $US1300 per month. If you stop taking it, you pile the weight back on. The drugs work so there’s high willingness to pay, which makes it a great business model. How society pays for them without bankrupting our healthcare system will be a big problem....
Click to expand...
I feel reluctant as taxpayer to pay with my taxes for some spineless fat grubs to lose fat.
And if treatment is stopped, they fatten again.great business
I just lost nearly 10kg since October so 1/9th of weight just with intermittent fasting.
$0 cost
 
Dona Ferentes said:
from the wires..
.
"This drug story started in the 1970s with the discovery that the hormone GLP-1 (glucagon-like-peptide-1) regulated blood sugar better than insulin for diabetics. But when GLP-1 was injected, it degraded before reaching the pancreas. GLP-1 was a failure.

"Then in the early 2000s, they extracted the saliva from a North American Gila monster (a venomous lizard) and injected it into rats. This sounds like a horror movie, but it’s 21st-century pharmaceutical R&D. The saliva was used to synthesise the first GLP-1 drugs that the body did not reject. GLP-1 became a phenomenal success.

The second wave of the GLP-1 drugs (liraglutide) by Novo Nordisk in 2010 had a peculiar side effect – injected rats starved themselves to death. Which is horrific, but it’s also interesting. With lower doses, rats ate less. When launched as the weight loss drug Saxenda in 2014, people lost 5 per cent of their body weight in a year.

The third wave of the GLP-1 diabetes drugs (semaglutide) was launched in 2017 by Novo Nordisk under the brand name Ozempic. Then things really took off. Ozempic was approved only for diabetes, but patients lost 15 per cent of their body weight in a year.
The drug was rebranded for weight loss in 2021 as Wegovy. Interestingly, it seemed to also curb compulsive behaviours such as drinking alcohol, gambling and smoking.

The point of this history lesson is there is half a century of dedicated research behind these drugs. Yet, the drugs are not without their challenges. The long-term side effects are unknown – only time will reveal this.

Ozempic is expensive at $US1300 per month. If you stop taking it, you pile the weight back on. The drugs work so there’s high willingness to pay, which makes it a great business model. How society pays for them without bankrupting our healthcare system will be a big problem....
Click to expand...
It's not just Ozempic though, there is a number of weight loss drugs and more being developed where injections are not needed.
Exciting time for those with obesity problems that can't be shifted. I think some people really need it, hence the gastric bypass operations.
We have to hope that competition will drive prices down.

 

Morgan Stanley: These ASX stocks are at risk from Ozempic​


A new report from Morgan Stanley has upgraded the outlook for the weight-loss drug market and named the ASX stocks most at risk from the rise of products like Ozempic.

Ozempic and similar weight-loss drugs – known as GLP-1s – took the world by storm last year, sending shares of drug developer Novo Nordisk and competitor Eli Lilly soaring as investors raced to tap into the demand.

In the new report, the investment bank’s analysts told clients that they predicted the still-nascent weight-loss drug market would grow to $US105 billion ($164 billion) by 2030, up from a previous estimate of $US77 billion.

a8c2da84f9907113279fca51a8b6893b13aae91a.jpg

... not Resmed or CSL, but WOW, COL, CFK, DMP, EDV, TWE; that is the supermarkets, fast food chains and alcohol outlets.

“We think the picture could be more nuanced,” Morgan Stanley’s brokers told their clients. “It is conceivable that GLP-1s drive increased awareness and interaction with the healthcare system among patients with obesity, leading to higher rates of diagnosis for obstructive sleep apnoea and ultimately some increased penetration to partially offset the patient losses ."
 
qldfrog said:
I feel reluctant as taxpayer to pay with my taxes for some spineless fat grubs to lose fat.
And if treatment is stopped, they fatten again.great business
I just lost nearly 10kg since October so 1/9th of weight just with intermittent fasting.
$0 cost
Click to expand...
Me too.

Perhaps there is a very small number of people who for this is entirely appropriate. I suspect that number is far smaller than for whom this drug is prescribed.

While by no means obese I can stack on weight pretty quickly. I know the reason, carb rich food and a few more Guinesses than appropriate, more often than appropriate :p

But if I want to lose weight, I know what to do and it does not involve any sort of medication... And it can drop off me very quickly.


Unfortunately for the large part it involves laying off the Guinness :( but also re-adjusting the mix of carbohydrate versus proteins and fats.

The science is out there and readily accessible, it just takes a little bit of willpower.
 
wayneL said:
Me too.

Perhaps there is a very small number of people who for this is entirely appropriate. I suspect that number is far smaller than for whom this drug is prescribed.

While by no means obese I can stack on weight pretty quickly. I know the reason, carb rich food and a few more Guinesses than appropriate, more often than appropriate :p

But if I want to lose weight, I know what to do and it does not involve any sort of medication... And it can drop off me very quickly.


Unfortunately for the large part it involves laying off the Guinness :( but also re-adjusting the mix of carbohydrate versus proteins and fats.

The science is out there and readily accessible, it just takes a little bit of willpower.
Click to expand...
Knowledge and will power indeed.
I do not say it is easy but meat and fat, low carbs( alcohol, sugar, starches) and low/no processed food and you can do it wo being hungry and still enjoy a good steak with vegies, not fries...
on the other end, a pill and gorging on hamburgers and nuggets, ice cream, cookies and booze..yeah the choice is easy, even worse, carbs and sugar /**** food is cheap , much less than good vegies and quality grass fed meat..and if the pill is paid by medicare.
it is a societal choice:
I believe by many ways modern western society is purposely, or at least without care ,making us sick for $ reasons, then getting more $ "healing" us with modern medicine, and Covid is not even a major test case: opioids , vit D deficiencies, obesity and diabetes, alzeihmer, sterility issues and ivf, etc etc
gpl1 just the latest in a long list, and in 10y we will be selling more drugs to sort the issues or side effects created by this one.
 
we demand you supply.

Some of Australia’s most popular telehealth providers are being labelled “nothing but online pharmacies” intent on circumventing Australia’s strict advertising and drug regulations in the relentless pursuit of profit.
There are calls from within parliament for a specific telehealth regulator as digital health industry insiders speak out about the practices of aggressive health start-ups they are accusing of “cowboy behaviour that’s endangering patients” including manufacturing a copycat formula of the popular weight-loss drug Ozempic in compounding pharmacies and distributing it to thousands of patients.

The Therapeutic Goods Administration is moving to try to ban the practice of supplying patients with sodium salt semaglutide manufactured in compounding pharmacy laboratories. Compounded medications, normally provided only in rare, highly individualised cases, are exempted under legislation from usual drug regulation mechanisms. The TGA is trying to have copycat semaglutide carved out from the exemption.

Commercial telehealth company Eucalyptus, which has 20,000 patients pursuing weight loss on the books of its online provider Juniper, is suppling salt semaglutide to a large number of those individuals, saying it can’t get supply of Ozempic.

“The nature of those drugs, in terms of them being untested, unproven potentially, we don’t know what their safety profile is, we don’t know what’s in them,” said Robyn Langham, TGA’s principal legal and policy adviser.

“And certainly in the US, it’s been established that clearly these drugs are different. So we don’t have any notion of safety, quality or efficacy and these drugs are being now distributed on a very, very large scale."
 
and now ...

Last week, Eli Lilly released the results of a highly anticipated clinical trial called SURMOUNT-OSA. The Phase III study assessed the efficacy and safety of tirzepatide — a 'GLP-1' drug that causes weight loss — in treating moderate-to-severe sleep apnea in obese adults. Eli-Lilly reported that its weight-loss drug, tirzepatide reduced the severity of sleep apnoea in 62% of the trial patients.

And Resmed was hit
 
This medico-legal doc gave a rundown of unwanted effects of semaglutide that are behind a growing tide of medical suits. Side effects begin at 7.00 and goes for 4 mins.

 
Mess with the human body as little as possible. It's unfathomable to most of us.
Can't count on doctors and pharma to know much, or care.

"The autonomic nervous system is a component of the peripheral nervous system that regulates involuntary physiologic processes including heart rate, blood pressure, respiration, digestion, and sexual arousal. It contains three anatomically distinct divisions: sympathetic, parasympathetic, and enteric."

 
finicky said:
Mess with the human body as little as possible. It's unfathomable to most of us.
Can't count on doctors and pharma to know much, or care.

"The autonomic nervous system is a component of the peripheral nervous system that regulates involuntary physiologic processes including heart rate, blood pressure, respiration, digestion, and sexual arousal. It contains three anatomically distinct divisions: sympathetic, parasympathetic, and enteric."

Click to expand...

Exactly,also valid for covid, flu...
Modern medecine is actually doing ravages...not that i deny amazing surgery procedures, vaccines,( no, Pfizer and Moderna are not vaccines).
But taking care of your body, what you feed on, breath, lifestyle is what makes the difference.
When we start toying with it, we usually break something else....
And it would be incredibly amazing and very unlikely if these ozempic treatments are not wrecking something else .
Not doing any damage would be in contradiction to evolution IMHO.
In a world where food is not food anymore and medecine does not care anymore for rhe patients, this treatment is a new golden goose, and imagine the ROI with the coming treatment of side effects...
 

Similar threads

basilio
Ozempic: Magic Pill or Devils Bargain?
Replies
10
Views
1K
sptrawler
sptrawler
Top